SW48 Xenograft Model Service for Colon Cancer

The SW48 Xenograft Model Service for Colon Cancer provides a robust, validated preclinical platform for evaluating therapeutic efficacy against a well-characterized colorectal adenocarcinoma cell line with wild-type KRAS and BRAF status. Alfa Cytology leverages rigorous quality control and standardized protocols to deliver reproducible SW48 xenograft data, supporting your oncology pipeline from early-stage pharmacology through translational proof-of-concept studies.

Overview of SW48 Xenograft Model for Colon Cancer

SW48 is a human colorectal adenocarcinoma cell line established from a patient-derived tumor, widely used in preclinical oncology research due to its well-defined molecular background. Genetically, SW48 harbors wild-type KRAS and BRAF, but carries a hyperactivating EGFR mutation, making it particularly relevant for studies targeting receptor tyrosine kinase signaling and for investigating acquired resistance to anti-EGFR therapies such as cetuximab. The cell line also exhibits wild-type TP53 and lacks PIK3CA/PTEN alterations, providing a relatively clean genetic background for dissecting EGFR-driven oncogenic mechanisms. In xenograft settings, SW48 tumors form reproducible subcutaneous or orthotopic grafts in immunodeficient mice, retaining key histological and transcriptomic features of human colorectal cancer, including glandular architecture and metabolic profiles consistent with glycolytic subtypes.

The SW48 xenograft model has been extensively validated in drug response studies, demonstrating sensitivity to HDAC inhibitors (e.g., MGCD0103) with significant tumor growth inhibition, and serving as a critical tool for evaluating bispecific antibodies and combination regimens. Notably, SW48 xenografts have been employed to model acquired resistance to cetuximab through continuous drug exposure, yielding resistant sublines that mirror clinical relapse patterns. The model is also amenable to luciferase labeling for non-invasive longitudinal monitoring, and transcriptomic analyses confirm that SW48-derived xenografts cluster closely with parental cell lines and patient tumor tissues, preserving molecular subtype characteristics essential for translational fidelity.

Figure 1. Morphological characteristics of the cell lines observed under a phase-contrast microscope. (Ahani, N, et al., 2020)

Cell Line Information: SW48

SW48 is a well-characterized human colorectal adenocarcinoma cell line maintained under standardized culture conditions. The table below summarizes essential biological, genetic, and culture characteristics relevant to preclinical xenograft applications.

Our Services

Alfa Cytology provides end-to-end SW48 xenograft model services tailored to your preclinical research objectives, from cell line expansion and quality assurance through in vivo implantation, tumor monitoring, and endpoint analysis. Our team ensures rigorous protocol adherence, comprehensive data reporting, and flexible study designs to accelerate your oncology drug development programs with confidence.

Workflow of SW48 Xenograft Model Construction

The construction of SW48 xenograft tumors follows a standardized, GLP-aligned workflow designed to ensure reproducibility, ethical compliance, and translational relevance. Each stage is executed with stringent quality controls to maintain model integrity and data fidelity.

1. Cell Line Preparation and Quality Control: SW48 cells are expanded from authenticated, low-passage stocks under GMP-aligned culture conditions. Prior to implantation, cells undergo viability assessment (trypan blue or automated counting), mycoplasma testing, and STR confirmation to ensure genetic stability and sterility.
2. Mouse Model Selection and Acclimatization: Immunodeficient strains (e.g., NOD/SCID or nude mice) are selected based on study objectives. Animals are acclimatized for 5-7 days under controlled environmental conditions, with health monitoring and randomization into treatment groups prior to tumor cell injection.
3. Tumor Cell Inoculation: SW48 cells are harvested at logarithmic growth phase, washed, and resuspended in a sterile matrix (e.g., serum-free medium mixed with Matrigel at a 1:1 ratio) to enhance engraftment. For subcutaneous models, 1 x 10^6 to 5 x 10^6 cells are injected into the flank; orthotopic models require surgical implantation into the cecal wall.
4. Tumor Growth Monitoring: Tumor dimensions are measured twice weekly using digital calipers, and volumes are calculated via the modified ellipsoid formula (length x width^2 x 0.5). For luciferase-labeled SW48 lines, bioluminescence imaging is performed weekly to monitor tumor burden non-invasively. Body weight and clinical signs are recorded concurrently.
5. Treatment Administration and Efficacy Assessment: Once tumors reach the target volume (typically 100-150 mm^3), animals are randomized into vehicle and treatment cohorts. Test compounds are administered via the designated route (oral, intraperitoneal, or intravenous) according to the study protocol. Tumor growth inhibition (TGI), regression rates, and time-to-progression are calculated.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC), molecular profiling (RNA/DNA extraction), and pharmacokinetic/pharmacodynamic analysis. Blood samples are collected for hematology and clinical chemistry. All tissues are archived for downstream validation.

Figure 2: Schematic workflow illustrating the derivation and construction of the SW48 Xenograft Model at Alfa Cytology.

Case Study-SW48 Xenograft Model Development

In a representative preclinical engagement, SW48 cells were expanded under controlled conditions and implanted subcutaneously into immunodeficient mice to establish a robust tumor growth baseline. The model demonstrated consistent engraftment rates and predictable growth kinetics, with tumors reaching evaluable volumes within 2-3 weeks post-implantation. Treatment cohorts received a candidate therapeutic agent or vehicle control, and tumor growth inhibition was assessed via longitudinal caliper measurements and terminal histopathological evaluation. Pharmacodynamic biomarkers were analyzed from tumor lysates to confirm target engagement. This case study illustrates the model's utility for generating reproducible efficacy data; specific quantitative results can be customized to align with client compounds and study designs upon request.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver SW48 xenograft data that meets the highest preclinical standards. Our integrated service model ensures seamless execution from study design to final report.

• Authenticated, low-passage SW48 cell banks with verified STR profiles and routine mycoplasma monitoring.
• Standardized xenograft protocols optimized for high engraftment rates and reproducible tumor growth kinetics.
• Flexible study designs supporting subcutaneous, orthotopic, and metastatic model configurations.
• Real-time tumor monitoring via caliper-based measurements and optional bioluminescence imaging for longitudinal tracking.
• Comprehensive endpoint analysis including histopathology, immunohistochemistry, molecular profiling, and biomarker quantification.
• Dedicated project management with transparent reporting, ensuring data integrity and regulatory readiness for IND-enabling packages.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated SW48 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and partner with Alfa Cytology for reliable, high-quality preclinical data. Reach out to our team and let us help you accelerate your oncology pipeline from concept to clinic.

For research use only. Not intended for any clinical use.